Skip to content

A single-center, prospective, open-labeled clinical study of stratified radiotherapy based on response to induction chemotherapy in patients with primary intracranial germ cell tumors

A single-center, prospective, open-labeled clinical study of stratified radiotherapy based on response to induction chemotherapy in patients with primary intracranial germ cell tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102955
Enrollment
Unknown
Registered
2025-05-22
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric intracranial germ cell tumor

Interventions

Germinoma group:Stratified radiotherapy based on response to induction chemotherapy
NGGCT group:Stratified radiotherapy based on response to induction chemotherapy

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in the study and sign the informed consent form; 2. Age 3 to 18 years old, gender not restricted; 3. Primary intracranial germ cell tumors confirmed by histology or clinically diagnosed; 4. Laboratory test results before enrollment are in compliance with: Blood routine: Platelet count >= 100×10^9/L; Absolute neutrophil count >= 1.5×10^9/L or white blood cell count >= 3.0×10^9/L; Hemoglobin >= 90g/L; Blood biochemistry: Aspartate aminotransferase (AST) = 50 points; 6. No previous radiotherapy, chemotherapy, immunotherapy, or targeted therapy; 7. Subjects with reproductive capacity are willing to take contraceptive measures during the study period.

Exclusion criteria

Exclusion criteria: 1. Recurrent intracranial germ cell tumor; 2. Has received any anti-tumor treatment other than surgery and traditional Chinese medicine for germ cell tumors before, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, etc.; 3. Has uncontrollable infections, unmanageable epilepsy and/or hypertension and/or hyperglycemia; 4. Has a history of other malignant tumors; 5. Cannot tolerate radiotherapy; 6. Has other reasons judged by the investigator as being unsuitable for participating in this study.

Design outcomes

Primary

MeasureTime frame
3 year-PFS;

Secondary

MeasureTime frame
3 year-OS;Objective response rate of tumors;adverse effects during radiotherapy and chemotherapy;

Countries

China

Contacts

Public ContactMawei Jiang

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

jiangmawei@xinhuamed.com.cn+86 21 2507 8635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026